الصفحة 14
الصفحة 14
Active Flow Control ; Papers contributed to the Conference “Active Flow Control 2006”, Berlin, Germany, September 27 to 29, 2006
This volume contains a well balanced combination of theoretical and experimental state-of-the-art results of Active Flow Control. It combines new developments in actuator technology, sensing, robust and optimal open- and closed-loop control and model reduction for control. Numerical and experimental applications are considered from aeronautics, turbo-machinery and combustors.
A Syrian Cultural Center in Germany
أهداف المشروع : 1- تعريف الجيل الجديد على الحضارة والثقافة السورية وتطوراتها. 2- بقاء السوريين على تواصل تراث وحضارة سوريا. 3- تأمين مكان للطلاب والباحثين السوريين للعمل على مشاريع وأعمال فكرية وابداعية تخدم التعريف بالثقافة السورية.
A Life (Un)Worthy of Living: Reproductive Genetics in Israel and Germany
This book presents the findings of a study into the social shaping of reproductive genetics in Germany and Israel, two exceptionally interesting social settings, which share a traumatic history. ‘This is a unique and courageous book. Yael Hashiloni-Dolev studied the field of reproductive genetics in Israel and Germany, and found out that while in Germany social, cultural, legal and religious conditions restrict the selection of embryos based on prenatal diagnosis, it is strongly encouraged in Israel. This unexpected finding is brilliantly analyzed by the author. Thus this excellent book must be read and discussed by social scientists, human geneticists, genetic counsellors, bio ethicists and medical students.'
70 Years of Levothyroxine
Presents the history, pharmacokinetics and pharmacodynamics of levothyroxine, discussing its role in the thyroid pathophysiology of patients of various ages and during pregnancy. It also describes the influence of levothyroxine on heart, bone and in cancer. When it was first synthesized in 1949, levothyroxine represented a significant advance in the treatment of hypothyroidism, providing a safe and effective treatment option for millions of hypothyroid patients around the globe. This synthetic form of thyroxine is now one of the most prescribed drugs in the world. Levothyroxine was first introduced by Merck KGaA,Darmstadt, Germany, in 1972, and since then the company has remained actively engaged in research on this mainstay of hypothyroidism treatment.
